Camostat and Artemisia Annua vs Placebo in COVID-19 Outpatients

Inclusion Criteria: * Age ≥18 years * Laboratory-confirmed SARS-CoV-2 infection within 3 days (of proposed consent) or the presence of symptoms or signs providing a high probability of COVID-19 disease who have symptoms within 7 days prior to diagnosis as determined by Infectious Disease specialist or treating physicians. * Outpatients. No previous hospitalization within the past 3 months. * Subjects must have at least one of the following high-risk features for clinical deterioration: * Hypertension * Diabetes mellitus * Moderate to severe Chronic Obstructive Pulmonary Disease or asthma * Cancer patients who have received any immunosuppressive drugs within a year from enrollment. * Obesity as defined by a body mass index \> 30 kg/m2. * Living in a nursing home or long-term facility * Underlying serious heart condition as determined by the treating physician * Immunocompromised subject as defined by the treating physician or by the Infectious Disease specialist * Ability to provide informed consent by the patient or healthcare proxy. * Ability to return for repeated testing and observation to the hospital. * Patients must have adequate organ and marrow function measured within the last 30 days as defined below: * platelets ≥100,000 * aspartate transaminase or alanine transaminase ≤3 times institutional upper limit of normal * creatinine ≤ 1.5 times institutional upper limit of normal OR * glomerular filtration rate ≥45 mL/min/1.73 m2 unless data exists supporting safe use at lower kidney function values, no lower than 30 mL/min/1.73 m2 Exclusion Criteria: * Severe COVID-19 is defined by one or more of the following: * blood oxygen saturation ≤ 90% * partial pressure of arterial oxygen to fraction of inspired oxygen ratio \< 300 * lung infiltrates ≥ 50% within 24 to 48 hours * Life-threatening COVID-19 is defined as one or more of the following: * respiratory failure * septic shock * multiple organ dysfunction or failure * Weight less than 45 kg. * Pregnant or breast-feeding females * Subjects on dialysis or with creatinine clearance \< 45 ml/min * Subjects who need antiviral administration due to severe viral diseases other than COVID-19, such as HIV, hepatitis B, and hepatitis C * Existing Division of Microbiology and Infectious Disease Toxicity Scale for determining the severity of adverse events grade 3 or greater. * Uncontrolled seizure disorder * Subjects with reflux esophagitis after chronic pancreatitis and gastrectomy surgery. * Patients with reflux esophagitis after surgery. * Known allergy to Artemisia annua or camostat mesilate. * Currently receiving any study medications for other indications. * Concurrent use of medication that would cause moderate or severe due to drug-drug interactions with study medication. Specifically: * Patients receiving Artemisia annua tea may not be currently taking strong inducers of CYP2A6, including phenobarbital and rifampin. * Receipt in the 12 hours prior to enrollment, or planned administration during the 14-day study period that treating clinicians feel cannot be substituted for another medication, of any of the following: amiodarone; cimetidine; dofetilide; phenobarbital; phenytoin; or sotalol. * Cancer patients receiving active immunosuppressive treatment cannot be enrolled unless they are on a treatment holiday with no antineoplastic treatment with 3 weeks of enrollment. * Patients with genetic problems such as galactose intolerance, Lapp lactase deficiency, or glucose-galactose malabsorption * Subjects who have a history of drug and/or alcohol abuse within 52 weeks before screening * Enrollment on other experimental therapies for COVID-19. * Inability to receive enteral medications * Patients with psychiatric illness/social situations that would limit compliance with study requirements. * Subjects who have a history of drug and/or alcohol abuse within 52 weeks before screening * Any other condition that in the opinion of the treating physician justifies exclusion from the study.